JP2022504236A5 - - Google Patents
Info
- Publication number
- JP2022504236A5 JP2022504236A5 JP2021518561A JP2021518561A JP2022504236A5 JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5 JP 2021518561 A JP2021518561 A JP 2021518561A JP 2021518561 A JP2021518561 A JP 2021518561A JP 2022504236 A5 JP2022504236 A5 JP 2022504236A5
- Authority
- JP
- Japan
- Prior art keywords
- indazole
- piperidine
- phenyl
- carboxamide
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740872P | 2018-10-03 | 2018-10-03 | |
| US62/740,872 | 2018-10-03 | ||
| PCT/US2019/054534 WO2020072797A1 (en) | 2018-10-03 | 2019-10-03 | Niraparib salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504236A JP2022504236A (ja) | 2022-01-13 |
| JP2022504236A5 true JP2022504236A5 (enExample) | 2022-11-04 |
| JP7472115B2 JP7472115B2 (ja) | 2024-04-22 |
Family
ID=68345029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518561A Active JP7472115B2 (ja) | 2018-10-03 | 2019-10-03 | ニラパリブ塩 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3860981B1 (enExample) |
| JP (1) | JP7472115B2 (enExample) |
| KR (1) | KR20210071022A (enExample) |
| CN (2) | CN118994103A (enExample) |
| ES (1) | ES2967517T3 (enExample) |
| TW (2) | TWI853841B (enExample) |
| WO (1) | WO2020072797A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021269115A1 (en) | 2020-05-08 | 2023-01-19 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
| EP4373491A1 (en) | 2021-07-19 | 2024-05-29 | JANSSEN Pharmaceutica NV | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| EP4712976A1 (en) | 2023-05-17 | 2026-03-25 | Tesaro, Inc. | Novel use of an inhibior of the a poly-adp ribose polymerase (parp) in the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (enExample) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| NZ586675A (en) * | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| EP3277321B1 (en) | 2015-04-01 | 2024-08-14 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| FI3478286T3 (fi) | 2016-06-29 | 2024-03-14 | Tesaro Inc | Menetelmiä munasarjasyövän hoitamiseksi |
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| EP3565844B8 (en) | 2017-01-09 | 2023-04-12 | Tesaro, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ， インコーポレイテッド | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
-
2019
- 2019-10-03 CN CN202411070879.7A patent/CN118994103A/zh active Pending
- 2019-10-03 KR KR1020217012838A patent/KR20210071022A/ko active Pending
- 2019-10-03 WO PCT/US2019/054534 patent/WO2020072797A1/en not_active Ceased
- 2019-10-03 TW TW108135909A patent/TWI853841B/zh active
- 2019-10-03 TW TW113130597A patent/TW202513550A/zh unknown
- 2019-10-03 CN CN201980078366.1A patent/CN113166071B/zh active Active
- 2019-10-03 EP EP19794786.4A patent/EP3860981B1/en active Active
- 2019-10-03 ES ES19794786T patent/ES2967517T3/es active Active
- 2019-10-03 JP JP2021518561A patent/JP7472115B2/ja active Active